The antiphospholipid syndrome (APS) is defined by the occurrence of venous and arterial
thromboses, often multiple, and recurrent fetal losses, frequently accompanied by a …

We performed a meta-analysis to determine whether aspirin has a significant protective
effect on risk of first thrombosis among patients with antiphospholipid antibodies (aPL+) …

Haematopoietic stem and progenitor cells are maintained by special microenvironments
known as niches in bone marrow,,,,,. Many studies have identified diverse candidate cells …

The clinical spectrum of the anti-phospholipid syndrome (APS) is not limited to vascular
thrombosis or miscarriages but includes additional manifestations that cannot be explained …

Obstetric antiphospholipid syndrome (APS) is now being recognized as a distinct entity from
vascular APS. Pregnancy morbidity includes> 3 consecutive and spontaneous early …

Recent reports have associated NCF2, encoding a core component of the multi-protein
NADPH oxidase (NADPHO), with systemic lupus erythematosus (SLE) susceptibility in …

Introduction Antiphospholipid syndrome (APS) is associated with the risk of both arterial and
venous thrombosis. However, it is not known which factors might determine the location of …

Objective To assess the role of Toll‐like receptors (TLRs) in antiphospholipid antibody (aPL)–
mediated vascular abnormalities in patients with primary arterial antiphospholipid syndrome …

The antiphospholipid syndrome (APS) is an autoimmune disease characterized by the
clinical features of recurrent thrombosis in the venous or arterial circulation and fetal losses …

One of the challenges of managing patients with antiphospholipid syndrome is the
prevention of rethrombosis (secondary prophylaxis). Risk stratification, ie traditional …